TRAILBLAZER-REAL US:
A Patient-Centered Study
For patients with mild cognitive impairment, Dementia or Alzheimer's Disease and their care partners.
*Care partners will be compensated for their time.
Enroll Now
TRAILBLAZER-REAL US:
The TRAILBLAZER-REAL US (TB-REAL) study aims to gather information about the journey of patients with early-stage Alzheimer's Disease (AD) or mild cognitive impairment, and the impact of donanemab, a medicine approved by the Food and Drug Administration (FDA) in 2024. The information gathered from this study will help improve the care for people with AD now and in the future.
TB-REAL will:
Collect and link longitudinal data from diverse patients with AD who are undergoing evaluation for amyloid-targeting therapies or are being treated with donanemab
Monitor disease progression, treatment outcomes, effectiveness, and safety
Involve care partners — the family member, friend or other person who is helping the patient with healthcare or healthcare decisions
Serve as a platform for affiliated studies in evolving treatment areas
Participation Benefits
For Patients and Care Partners
- You will be part of a community of thousands of patients and care partners who support safe and effective treatment for mild cognitive impairment, dementia and AD
- You and your healthcare provider can talk about TB-REAL during your clinic visits
- You will contribute scientific knowledge to help make care better for you and future generations
- There is no cost to you
- Care partners will be compensated for participating in 30-minute checks-ins with a study team member every six months
For Healthcare Providers
- TB-REAL is designed to work with healthcare provider's existing standard of care
- Patients/care partners sign themselves up for TB-REAL; there are no forms for healthcare providers to complete
- Education resources and messaging provided to support healthcare provider/patient discussions, enrollment and questions
- The study is generalizable for research purposes for different types of healthcare providers and care settings
- Healthcare providers may have potential publication opportunities and access to future studies
Ready to enroll?
Enroll NowPremier is partnering with Lilly and OM1 for this study. Clicking this link will redirect you to an OM1 enrollment page. Please see OM1's privacy policy.
Resources
Download helpful flyers and conversation guides for healthcare providers and patients.
Sign-Up Instructions for Patients and Care Partners (PDF)
This flyer describes the opportunity for patients with mild cognitive impairment, dementia or AD - and their care partners - to participate in TB-REAL. It provides a study overview and covers who can sign up with sign-up instructions.
Download
Overview for Healthcare Providers (PDF)
This document provides an overview of the study, benefits of encouraging your patients to participate, eligibility, time commitment, and instructions on how to sign up.
DownloadShared Decision-Making Resource for Patients, Care Partners, and Healthcare Providers (PDF)
These conversation guides help patient/care partner/healthcare provider conversations about the opportunity to participate in the TB-REAL study in a question and answer format.
Healthcare providers can use the resource during appointments when developing care plans with the patient and care partner as a supplement to the sign-up instructions for patients and healthcare partners.
Patients and their care partners can use the resource to decide if participating in TB-REAL is right for them.
Key Driver Framework (PDF)
Explore this solution-driven resource for helping health systems select strategies and tools to improve patient care at the system level and point of care for specific healthcare conditions. This framework provides downloadable links gleaned from project insights that help achieve the main desired outcome. The framework covers operations and high-level clinical categories.
DownloadVirtual Event: Generating Real-World Evidence for Alzheimer's Disease Research: How Your Parents and Care Partners Can Enroll in TB-REAL
Date:
Thursday, September 25, 2-2:45 p.m. ET
Speakers:
Brent P. Forester, MD, MSc.
Chief and Chairman, Department of Psychiatry, Tufts Medical
Center
Co-Physician Executive, Neuroscience and Behavioral Health
Service Line, Tufts Medicine
Valeria C. Baldivieso, MD
Memory Care Medical Director
AdventHealth Medical Group Memory Care | Central Florida
Division
Description:
Early-stage detection of mild cognitive impairment, dementia and
Alzheimer's Disease remains a critical challenge. And when timely
intervention can improve outcomes, it's more important than ever to
participate in research opportunities to help understand the patient
journey.
Join us for a virtual event where experts will discuss:
- Patient and care partner enrollment process in Eli Lilly and Company's “Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients with Early Symptomatic Alzheimer's Disease (TRAILBLAZER-REAL US)” study, and how your health system can participate as a study site
- Measuring care partner stress
- Using clinical decision support (CDS) alerts to identify eligible patients
- Qualitative insights shared by dementia and Alzheimer's Disease experts on the importance of real-world data collection to better understand the journey of early-stage Alzheimer's Disease patients and associated care partner stress
- The future of dementia care
TB-REAL: Understanding the Patient Journey with Alzheimer's Disease A New Observational Study
This short paper reviews the burden of AD, expert insights from in-depth interviews, health access considerations (e.g., race, geography and income) and how patients can sign up for TB-REAL.
Download Whitepaper
Let's get started
Enroll NowPremier is partnering with Lilly and OM1 for this study. Clicking this link will redirect you to an OM1 enrollment page. Please see OM1's privacy policy.
© Premier Inc. - All Rights Reserved. Privacy Policy.